Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;5(1-2):1-14.
doi: 10.18632/genesandcancer.3.

ALK-rearrangements and testing methods in non-small cell lung cancer: a review

Rodney E Shackelford  1 , Moiz Vora  1 , Kim Mayhall  2 , James Cotelingam  1
Affiliations
Review

ALK-rearrangements and testing methods in non-small cell lung cancer: a review

Rodney E Shackelford et al. Genes Cancer. 2014 Apr.

Abstract

The anaplastic lymphoma tyrosine kinase (ALK) gene was first described as a driver mutation in anaplastic non-Hodgkin's lymphoma. Dysregulated ALK expression is now an identified driver mutation in nearly twenty different human malignancies, including 4-9% of non-small cell lung cancers (NSCLC). The tyrosine kinase inhibitor crizotinib is more effective than standard chemotherapeutic agents in treating ALK positive NSCLC, making molecular diagnostic testing for dysregulated ALK expression a necessary step in identifying optimal treatment modalities. Here we review ALKmediated signal transduction pathways and compare the molecular protocols used to identify dysregulated ALK expression in NSCLC. We also discuss the use of crizotinib and second generation ALK tyrosine kinase inhibitors in the treatment of ALK positive NSCLC, and the known mechanisms of crizotinib resistance in NSCLC.

Keywords: Anaplastic lymphoma kinase; crizotinib; non-small cell lung cancer; pulmonary adenocarcinoma.

PubMed Disclaimer

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917. - PubMed
    1. Ettinger DS, Akerley W, Bepler G, et al. NCCN Non-Small Cell Lung Cancer Panel Members. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740–801. - PubMed
    1. Hsiao SH, Chung CL, Lee CM, et al. Suitability of Computed Tomography-Guided Biopsy Specimens for Subtyping and Genotyping of Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2013;S1525-7304(13):00130–7. - PubMed
    1. Alberg AJ, Brock MV, Ford JG, Samet JM, Spivack SD. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e1S–29S. - PMC - PubMed
    1. SEER Cancer Statistics Review. Washington DC: US National Institutes of Health. National Cancer Institute; 1973-2008.